Cetera Investment Advisers Boosts Stake in Pfizer Inc. $PFE

Cetera Investment Advisers grew its holdings in Pfizer Inc. (NYSE:PFE) by 2.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,213,627 shares of the biopharmaceutical company’s stock after purchasing an additional 66,534 shares during the period. Cetera Investment Advisers’ holdings in Pfizer were worth $90,239,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Brighton Jones LLC boosted its stake in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after buying an additional 618,117 shares during the period. Revolve Wealth Partners LLC increased its position in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares during the last quarter. United Bank raised its stake in shares of Pfizer by 12.4% in the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after acquiring an additional 6,415 shares during the period. Sei Investments Co. raised its stake in shares of Pfizer by 31.5% in the 2nd quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock valued at $63,889,000 after acquiring an additional 631,523 shares during the period. Finally, HUB Investment Partners LLC lifted its holdings in shares of Pfizer by 45.3% in the 2nd quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock worth $2,480,000 after acquiring an additional 31,896 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Up 0.8%

Shares of NYSE PFE opened at $25.02 on Friday. The stock has a market cap of $142.62 billion, a P/E ratio of 19.10 and a beta of 0.35. The business’s fifty day simple moving average is $25.13 and its 200-day simple moving average is $26.18. Pfizer Inc. has a 12-month low of $23.11 and a 12-month high of $28.75. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The firm had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.Pfizer’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio is presently 131.30%.

Wall Street Analysts Forecast Growth

A number of research firms have commented on PFE. Morgan Stanley upped their price target on Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price for the company in a research report on Tuesday, June 9th. HSBC lowered shares of Pfizer from a “buy” rating to a “hold” rating and cut their price target for the stock from $32.00 to $28.00 in a research note on Monday, July 6th. Finally, Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $28.50.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA accepted Pfizer’s supplemental application for Talzenna plus Xtandi under Priority Review, a sign regulators are giving the prostate cancer expansion a faster path forward. Reuters article
• Positive Sentiment: Options activity was unusually heavy, with traders buying far more call options than normal, suggesting some investors are positioning for further upside in PFE.
• Neutral Sentiment: Articles discussing Pfizer’s roughly 7% dividend yield may help support the stock by reinforcing its income appeal, but they do not change the underlying business outlook. Motley Fool article
• Neutral Sentiment: Broader commentary on Pfizer’s oncology valuation suggests investors are still debating whether the company’s pipeline can justify a higher multiple. Kalkine Media article
• Negative Sentiment: Ongoing expanded patent litigation tied to mRNA vaccine technology remains a legal overhang and could create additional costs or uncertainty for Pfizer’s legacy COVID-19 franchise. Yahoo Finance article
• Negative Sentiment: Separately, policy risk remains a concern after reports that the Trump administration is considering steep tariffs on generic drugs, which could increase pressure across the pharmaceutical sector. Bloomberg article

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.